泊马度胺用于治疗多发性骨髓瘤
[Pomalidomide for multiple myeloma].
作者信息
Dougé Aurore, Lemal Richard, Chaleteix Carine
机构信息
CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
CHU de Clermont-Ferrand, service d'hématologie clinique adulte et de thérapie cellulaire, 63003 Clermont-Ferrand, France; Clermont université, université d'Auvergne, EA7283, CIC501, BP 10448, 63000 Clermont-Ferrand, France.
出版信息
Bull Cancer. 2017 Sep;104(9):707-713. doi: 10.1016/j.bulcan.2017.04.005. Epub 2017 Jun 2.
Pomalidomide is a second-generation immunomodulatory drug (IMID). Its efficiency overtakes its predecessors' (thalidomide, lenalidomide), with less toxicity. It is indicated in the treatment of refractory or relapsed multiple myeloma, associated to dexamethasone. It is available in France since 2013, following the results of different studies.
泊马度胺是第二代免疫调节药物（IMID）。其疗效超过了其前代药物（沙利度胺、来那度胺），且毒性更低。它被用于治疗与地塞米松联合使用的难治性或复发性多发性骨髓瘤。自2013年不同研究取得成果后，它在法国上市。
Zotero 插件